Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
NCT01206504 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2022-02-22
Summary
This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.
Conditions
- West Nile Virus Infection
Interventions
- BIOLOGICAL
-
MGAWN1
Humanized monoclonal to West Nile virus. Dose=30mg/kg
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH - lead INDUSTRY
Eligibility
- Min Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Host Response to Infection and Treatment in Filarial Diseases
NCT00001230 ·Status: RECRUITING
-
Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali
NCT02206451 ·Status: COMPLETED
-
CS DNA MVA Trial in Mampong, Ghana
NCT00377494 ·Status: WITHDRAWN ·Phase: PHASE1
-
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
NCT07235020 ·Status: COMPLETED ·Phase: PHASE2
-
Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP
NCT06881732 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults
NCT01624961 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
NCT07149753 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
NCT02098590 ·Status: COMPLETED ·Phase: NA
-
Malaria Vaccine for Children in Mali
NCT00740090 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults
NCT04268420 ·Status: UNKNOWN ·Phase: PHASE1
-
Collection of Biological Material From Pregnant Women in a Malarial Region
NCT01862783 ·Status: TERMINATED
-
Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria
NCT00414336 ·Status: COMPLETED ·Phase: PHASE1
-
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
NCT05084560 ·Status: TERMINATED ·Phase: PHASE1
-
Miltefosine to Treat Mucocutaneous Leishmaniasis
NCT01050907 ·Status: COMPLETED ·Phase: PHASE2
-
Experimental Human Malaria Infection by PfSPZ
NCT01086917 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults
NCT04296279 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers
NCT03163121 ·Status: COMPLETED ·Phase: PHASE1
-
Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)
NCT00340574 ·Status: COMPLETED ·Phase: PHASE1
-
A Human Controlled Infection Study with Neisseria Lactamica in Malian Adults
NCT04665791 ·Status: COMPLETED ·Phase: NA
-
Diagnosis and Treatment of Leishmania Infections
NCT00344188 ·Status: RECRUITING
-
Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis
NCT06798415 ·Status: RECRUITING ·Phase: PHASE2
-
Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)
NCT01434381 ·Status: COMPLETED ·Phase: PHASE1
-
Preventing the Spread of Malaria in Mali
NCT01360112 ·Status: COMPLETED
-
A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19
NCT04627584 ·Status: UNKNOWN ·Phase: PHASE2
-
Experimental Vaccine for Plasmodium Falciparum Malaria
NCT00340431 ·Status: COMPLETED ·Phase: PHASE1